Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 21:12:1875-1887.
doi: 10.2147/PPA.S169354. eCollection 2018.

Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center

Jochen Hefner  1 , Sara Berberich  2 , Elena Lanvers  3 , Maria Sanning  4 , Ann-Kathrin Steimer  5 , Volker Kunzmann  6
Affiliations

Patient-doctor relationship and adherence to capecitabine in outpatients of a German comprehensive cancer center

Jochen Hefner et al. Patient Prefer Adherence. .

Abstract

Purpose: The prescribing of oral chemotherapy agents has introduced the new challenge of ensuring patients' adherence to therapy. Aspects of a close patient-doctor relationship are reported to be correlated with adherence to oral anticancer drugs, but data on capecitabine are scarce.

Patients and methods: Sixty-four outpatients with a diagnosis of cancer and prescribed capecitabine were recruited from a German Comprehensive Cancer Center. We used the Patient-Doctor Relationship Questionnaire (PDRQ-9), the Medical Adherence Rating Scale (MARS), the Beliefs about Medicines Questionnaire (BMQ), and the Satisfaction with Information about Medicines Scale (SIMS) to assess patients' perceptions and behavior. Medical data were extracted from the charts.

Results: Non-adherence was reported by 20% of the 64 participants. The perceived quality of the patient-doctor relationship was high in general, but it did not emerge as a predictor of adherence in our survey (odds ratio [OR]=0.915, P=0.162, 95% CI=0.808-1.036). However, beliefs about medicine (OR=1.268, P<0.002; 95% CI=1.090-1.475) as well as satisfaction with information about medicine (OR=1.252, P<0.040, 95% CI=1.010-1.551) were predictors of adherence and the quality of the patient-doctor relationship was correlated with both variables (r=0.373, P=0.002 for SIMS sum score; r=0.263, P=0.036 for BMQ necessity/concern difference). Overall, adherence to capecitabine was high with a conviction that the therapy is necessary. However, concerns were expressed regarding the long-term effect of capecitabine use. Patients have unmet information needs regarding interactions of capecitabine with other medicines and the impairment of their intimate life.

Conclusions: In order to ensure adherence to capecitabine, our results seem to encourage the default use of modern and perhaps more impersonal means of information brokerage (eg, email, internet). However, the contents of some of patients' informational needs as well as the associations of patients' beliefs and satisfaction about the information received suggest a benefit from a trustful patient-doctor relationship.

Keywords: adherence; beliefs in medication; capecitabine; oral anticancer drugs; patient–doctor relationship; satisfaction with information about medicines.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Perceived burden of side effects on a visual analog scale (VAS, 0–100).
Figure 2
Figure 2
Participant satisfaction with information received (Satisfaction with Information about Medicines Scale, n=64).
See this image and copyright information in PMC

References

    1. American Cancer Society Cancer Facts & Figures. 2016. [Accessed March 1, 2018]. Available from: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
    1. Carrillo E, Navarro SA, Ramírez A, et al. 5-Fluorouracil derivatives: a patent review (2012–2014) Expert Opin Ther Pat. 2015;25(10):1131–1144. - PubMed
    1. Weinberg BA, Marshall JL, Hartley M, Salem ME. A paradigm shift from one-size-fits-all to tailor-made therapy for metastatic colorectal cancer. Clin Adv Hematol Oncol. 2016;14(2):116–128. - PubMed
    1. Mcquade RM, Stojanovska V, Bornstein JC, Nurgali K. Colorectal cancer chemotherapy: the evolution of treatment and new approaches. Curr Med Chem. 2017;24(15):1537–1557. - PubMed
    1. Twelves C. Vision of the future: capecitabine. Oncologist. 2001;6(Suppl 4):35–39. - PubMed